SCHEMBL1363069

SCHEMBL1363069

O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4=O)c3)n2)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 18/20 0.83
EGFR P00533 13/20 0.83
ERBB2 P04626 13/20 0.83
KDR P35968 9/20 0.83
STK3 Q13188 8/20 0.83
MAP4K5 Q9Y4K4 8/20 0.83
RET P07949 8/20 0.83
LCK P06239 8/20 0.83
FGFR1 P11362 6/20 0.83
TAOK1 Q7L7X3 6/20 0.83
AURKB Q96GD4 6/20 0.83
MAP4K4 O95819 6/20 0.83
FYN P06241 5/20 0.83
MAP4K2 Q12851 5/20 0.83
AURKA O14965 4/20 0.83
PRKD3 O94806 4/20 0.83
INSR P06213 4/20 0.83
LYN P07948 4/20 0.83
FLT4 P35916 4/20 0.83
FRK P42685 4/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1362868 0.95 IGF1R (0.84) IGF1REGFRERBB2KDRSTK3
SCHEMBL1364343 0.91 IGF1R (1.00) IGF1REGFRERBB2KDRSTK3
SCHEMBL1363078 0.91 IGF1R (1.00) IGF1REGFRERBB2KDRSTK3
SCHEMBL1363910 0.90 IGF1R (0.77) IGF1REGFRERBB2KDRSTK3
SCHEMBL1361783 0.88 IGF1R (0.81) IGF1REGFRERBB2KDRSTK3
SCHEMBL1361835 0.88 IGF1R (1.00) IGF1REGFRERBB2KDRSTK3
SCHEMBL1362527 0.87 IGF1R (0.83) IGF1REGFRERBB2KDRSTK3
SCHEMBL1363154 0.87 EGFR (0.73) IGF1REGFRERBB2KDRSTK3
SCHEMBL1363318 0.86 EGFR (0.83) IGF1REGFRERBB2KDRSTK3
SCHEMBL1362563 0.86 IGF1R (0.71) IGF1REGFRERBB2KDRSTK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US claimed
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US disclosed
EP-2222682-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2010-09-01 EP disclosed
US-20090253723-A1 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
WO-2009070516-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253723-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 IGF1R 1941/4885EGFR 591/4885ERBB2 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.